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Abstract Positron emission tomography (PET)-CT was rec-
ommended in updated international guidelines for staging/
restaging of diffuse large B-cell lymphoma (DLBCL) and
follicular lymphoma (FL). In FL, PET was previously
regarded as a research application only. This review concen-
trates on new publications related to PET in these diseases. In
DLBCL, PET appears appropriate for staging using prognos-
tic indices established with CT and baseline PET parameters,
e.g. metabolic tumour volume, are prognostic of outcome.
Early complete metabolic response (CMR) predicts end-of-
treatment CMR with excellent prognosis. Patients without
CMR at interim should not have treatment altered, but have
a worse prognosis, and patients with other high risk features
may need closer monitoring. The end-of-treatment scan is
confirmed as the standard for remission assessment using
Deauville criteria, which are also predictive for patients un-
dergoing ASCT. In FL, PET is more sensitive for staging than
CT but misses bone marrow involvement. PET-CT identifies
patients at risk of progression after induction chemotherapy
better than CT.
Keywords Positron emission tomography . Diffuse large B
cell lymphoma . Follicular lymphoma . Diagnostic imaging .
Computed tomography . Cancer staging
Introduction
Posi t ron emission tomography (PET) with 18F-
fluorodeoxyglucose (FDG) has been used to image patients
with diffuse largeB-cell lymphoma (DLBCL) for over 25 years,
whereas its potential utility in follicular lymphoma (FL) has
only been appreciatedmore recently. Both aremalignancies that
are highly FDG-avid with uptake in more than 90–95 % of
cases [1]. Changes in FDG uptake are frequently used for mon-
itoring treatment both during chemotherapy and at completion
of treatment. International guidelines [2••, 3••] support the use
of PET-CT as the standard imaging modality for staging in
DLBCL and FL and for remission assessment in DLBCL and
in FL for patients undergoing immunochemotherapy.
However, the use of FDG-PET-CT continues to evolve
with developments in the management of lymphoma, and this
review will focus on these developments in DLBCL and FL.
PET-CT provides more accurate staging than CT with better
detection of all disease sites, but particularly extranodal sites,
which are frequent in non-Hodgkin lymphoma (NHL).
Accurate staging enables better prognostication, choice of
therapy and comparison of results in clinical trials. We will
review the additional value of PET-CT to already established
prognostic indices. PET-CT is also more accurate than CT in
remission assessment. In DLBCL where the aim of treatment
is cure, an accurate assessment of remission is essential so that
fit patients who are not in remission can be offered salvage
therapy. This is not the same for FL, which is generally incur-
able. However, recent evidence suggests that complete remis-
sion assessed by PET-CT is strongly prognostic and may be
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used to guide intensity of follow-up or further treatment.
Another feature of PET-CT is its ability to show metabolic
response early during chemotherapy, which tends to correlate
well with the final outcome of treatment. This can be used to
select non-responding patients for a change in therapy and/or
responding patients for potential de-escalation, as has been
tested in HL. We review the current evidence for these ap-
proaches in DLBCL and FL.
Diffuse Large B-Cell Lymphoma
DLBCL is the most common aggressive NHL worldwide and
is curable in about 60–70 % of patients with a combination of
anthracycline-containing chemotherapy and rituximab (e.g.
RCHOP). For relapsed disease, high-dose chemotherapy and
autologous stem-cell rescue is the standard treatment; howev-
er, it is not feasible in elderly patients with co-morbidities and
in general seems to be less effective since the introduction of
rituximab to first-line treatment. Pre-treatment prognosis is
traditionally estimated using the International Prognostic
Index (IPI) or one of its modifications, but response to first-
line treatment is another very important prognostic factor.
Staging—PET for Risk Stratification Pre-treatment
PET-CT is regarded as mandatory for staging patients with
DLBCL because (i) CT alone understages patients by missing
extranodal disease and (ii) a staging scan is required to identify
initial disease sites when reporting end-of-treatment scans
[2••]. Changes occur during treatment that need to be distin-
guished from lymphomatous involvement, which is evident
on the staging scan. Changes may be FDG-avid but represent
inflammation, infection and/or stimulation of normal marrow
rather than lymphoma [4]. Recent publications have examined
the effect of the more accurate staging with PET-CT on the
prognostic ability of IPI [5, 6]. There is also growing interest
in the significance of disease features on baseline PET, partic-
ularly in relation to the extent of extranodal involvement and
total disease burden, both of which show promising prognos-
tic value [7, 8, 9•].
PET-CT Staging and Prognostic Indices
There are three prognostic indices available to risk-stratify
patients: the IPI [10], the revised IPI (R-IPI) [11] introduced
to account for improved prognosis after rituximab and the
most recent National Comprehensive Cancer Network IPI
(NCCN-IPI) [12] with further refinement based on grading
some of the prognostic factors.
All use clinical factors - age, performance status (PS) and
lactate dehydrogenase (LDH) level and imaging defined fac-
tors - Ann Arbor stage and extranodal involvement. These
indexes were formulated using CT imaging. PET, now recom-
mended for staging, upstages a significant proportion of pa-
tients, specifically detecting more extranodal disease, in par-
ticular with respect to bone marrow involvement [2••].
Recent studies examined the effect of PET upstaging on the
performance of prognostic indices. El-Galaly and colleagues
[5] evaluated stage, extranodal involvement and prognostic
indices in 443 newly diagnosed patients with DLBCL staged
with PET-CT, treated with R-CHOP or R-CHOP-‘like’ che-
motherapy. PET-based IPI, R-IPI and NCCN-IPI were all pre-
dictive of outcome. Patients with very good (R-IPI) or low risk
(NCCN-IPI) had excellent outcomes: 3y-PFS was 100 %
(95 % confidence interval 88, 100) [n=50] for very good risk
and 3y-PFS and OSwere 100% (88, 100) [n=54] for low-risk
patients. However, the IPI and R-IPI failed to identify the
group who are unlikely to be cured with RCHOP, with 3y-
PFS >50 % for the poor risk group, but the NCCN-IPI was
better at identifying this group (3y-PFS 33 % and OS 40 %).
Significance of Extranodal Disease Extent
Another emerging theme in the study by El-Galaly et al. is the
strong prognostic value of the extent of extranodal involve-
ment. Two thirds of patients had extranodal disease on PET-
CT, and significantly more treatment failures occurred with an
increasing number of involved extranodal sites. By example,
3y-PFS was 25 % (7, 53) in patients with four or more
extranodal sites compared to 79 % (71, 87) in patients with
nodal disease only. Corresponding 3y-OS was 36 % (16, 56)
vs 82 % (66, 98), respectively. Patients with extranodal in-
volvement were older and had worse PS, more B symptoms
and a higher prevalence of raised LDH. The extranodal sites
associated with worse PFS and OS were bone marrow, pleura
and gynaecological organs [13].
Using Disease Burden/Metabolic Tumour Volume
Bulk is regarded as an adverse prognostic indicator in
DLBCL, at least in patients with otherwise good prognosis
[14]. It is commonly measured as the largest dimension of
the largest mass. Metabolic tumour volume (MTV) is a more
sophisticated, albeit time-consuming measurement of total
disease burden based on volumetric measurement and meta-
bolic activity. MTV is calculated by adding volumes of tu-
mour, selected using a standardised uptake value (SUV) typ-
ically ≥2.5 or a percentage of the maximum SUV in areas of
tumour [15, 16]. Recent publications report thatMTV predicts
prognosis [17, 18] better than bulk [9•]. An inherent problem,
as with all measurements with a continuous distribution, is
where to draw the cutoff between ‘high’ and ‘low’ MTV. A
range of thresholds has been reported from 220 to 550 cm3,
derived from receiver operating characteristic curves [9•, 17,
18]. The cutoff is influenced by the characteristics of the study
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population, with patients with earlier stage nodal disease
only [17] having lower cutoffs than patients with high-
risk more advanced disease [18]. Patients with low
MTV tend to have better outcomes, with 3y-PFS 77–
92 %, compared with patients with high MTV who
have worse outcomes, 3y-PFS 48–56 % [9•, 17, 18],
but again not sufficiently poor to consider treatment
escalation. Mikhaeel et al. [9•] combined baseline
MTV with early response assessment using Deauville
scores at 2 cycles in 147 consecutive unselected patients
treated for DLBCL with R-CHOP at a single institution.
Patients could be separated into three distinct prognostic
groups—good risk (low MTV regardless of PET-2
response), intermediate risk (high MTV, with CMR at
2 cycles) and poor risk (high MTV, no CMR at 2 cycles,
Deauville scores 4, 5). 5y-PFS was >90 %, 58 % and
30 %, respectively (median FU=3.8 years). The poor
risk group contained 31 % of patients who experienced
58 % of the study events. These results demonstrate the
previously unexplored interaction between pre-treatment
prognosis and early response which enables better prog-
nostication at an individual patient level. Validation of
these results in larger prospective studies is warranted,
as such an approach could improve on the prognostic
power of interim PET (Fig. 1).
The Debate About Bone Marrow Biopsy
The debate about bonemarrow biopsy in DLBCL continues to
vex haemato-oncologists [19]. The high sensitivity of PET-CT
for focal involvement in DLBCL in the bone marrow is well
documented [20]. In two retrospective [21, 22] and one pro-
spective [23] study involving 590 patients with newly diag-
nosed DLBCL, staged by PET-CT, no patients were changed
to advanced stage based on bone marrow biopsy (BMB)
alone, similar to findings in HL.
The contentious issue is whether the detection of low-
volume involvement [24] (∼10–20 %) or the presence of dis-
cordant low-grade lymphoma in the marrow [25], which can
be missed on PET, warrants BMB in all patients, or at least in
patients with no evidence of bone marrow involvement on a
staging PET-CT scan. Neither low-volume disease [26] nor
indolent NHL [27] in the marrow has been demonstrated to
affect outcome, independent of the IPI.
In the recent study by El-Galaly et al. [5] discussed above,
12/443 patients (3 %) had large cells in the marrow and 18
patients (4 %) had indolent NHL in the marrowwhen PET-CT
scans did not demonstrate bone marrow involvement. This
means that 26 patients with a ‘negative’ PET-CT scan for
marrow involvement would need to undergo biopsy to detect
a single case of missed large cells in the marrow. In a recent
report by Cerci et al. [23], neither bone marrow involvement
on PET-CT nor BMB alone adversely affected survival. Only
patients with bone marrow involvement detected on both
PET-CT and BMB at diagnosis had inferior prognosis, sug-
gesting that disease burden in the marrow rather than marrow
involvement per se influences prognosis. This can be readily
appreciated by viewing the PET-CTscan in the multidisciplin-
ary meeting. Nevertheless, haemato-oncologists who believe
a BMB will influence patient management will wish to per-
form biopsy. We however advocate a selective approach,
using BMB where results may influence prognosis or treat-
ment, rather than routine biopsy in all patients [3••].
Response Assessment—PETat Interim, End of Treatment
and Prior to Autologous Stem Cell Transplant
Post-treatment remission assessment is important, as cure is
the goal of treatment in DLBCL. PET-CT is the standard
method in international guidelines [3••] and is widely used
in routine practice. Nevertheless, several points are worth
addressing:
1. What is the positive predictive value for end-of-treatment
PET and is residual PET activity sufficient to initiate fur-
ther or salvage treatment?
2. What is the prognosis of complete metabolic response
(CMR) on end-of-treatment PET and is it independent of
pre-treatment characteristics?
Fig. 1 Coronal CT, PET and fused images are shown of patients with
high metabolic tumour volume at baseline which is predictive of inferior
prognosis. The patient in the top panel (a) had bulk disease by
conventional assessment of maximal tumour dimension; the patient in
the bottom panel (b) does not have bulky disease
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3. Can interim PET predict end-of-treatment PET result
early?
4. Can interim PET be used to escalate treatment for poor
responders?
Several studies have shown that residual activity in sites of
previous disease on PET-CT, normally defined as Deauville
score 4–5, is strongly predictive of residual disease. In R-
CHOP-treated patients, progression-free survival (PFS)
ranges from 24 to 35 % for positive end-of-treatment PET
[28••, 29••]. This may be considered high enough to consider
further treatment without biopsy confirmation. However, we
would recommend that biopsy should be considered whenev-
er possible to exclude the less common false-positive cases
usually histologically reported as xanthomatous granulomato-
sis [2••]. Ultimately, the decision depends on the balance be-
tween the type of biopsy required (e.g. imaging-guided versus
open surgery) and the intensity of treatment being considered
(e.g. consolidation radiotherapy versus autologous stem cell
transplant (ASCT)). Consideration of pre-treatment prognosis
and response on interim imaging may also help the decision.
The negative predictive value of end-of-treatment PET is
high, and most patients enjoy a long-term remission or cure.
However, recent evidence also suggests that high-risk patients
who achieve CMR still have a considerable risk of relapse. In
a population-based study of 223 consecutive patients treated
with R-CHOP-like immunochemotherapy [34], NCCN-IPI
and R-IPI remained predictive of relapse irrespective of CT-
or PET-defined remission status. Patients with NCCN-IPI 6–8
had a dismal outcome and higher risk of CNS relapse, whether
or not they achieved CMR. The median age in this group,
however, was 75 years. None responded to salvage treatment.
In this elderly high-risk group, the authors suggested that al-
ternative therapeutic approaches, e.g. novel agents, may be the
only prospect for cure.
Early response assessment using interim PET is a more
controversial area in DLBCL due to variable results reported
in studies [30–37] and the debate on what action, if any,
should be taken. We first examine the prognostic significance
of interim PET negative and positive results and subsequently
what action might be appropriate.
Studies demonstrate that 60–80 % of patients achieve
CMR after 1–4 cycles of systemic therapy and tend to have
an excellent PFS, usually in excess of 75–80 % [28••, 29••,
38]. More recent evidence also shows that achievement of
early CMR predicts final CMR with very low risk of conver-
sion to PET positivity (i.e. progression) after treatment [28••,
29••, 39].
Mamot el al. [28••] recently reported prospective results in
138 patients with DLBCL treated with R-CHOP-14 with re-
sponse assessed using PET-CT. This important study
employed standardised methods for PET with a common im-
aging protocol and strict observance of timing of scans in
relation to chemotherapy. Treatment was not adapted accord-
ing to interim PET, although patients with progression went
off-study, suggesting that clinicians considered that it was un-
acceptable to continue with standard treatment in the presence
of clear evidence of progression on interim PET, in line with
recent international recommendations [2••]. There was a
higher proportion of events than anticipated, likely because
radiotherapy was included as an event, but the authors found
similar results when using PFS as the end point. Analysis
during the study used older International Harmonization
Project reporting criteria [40], but a post hoc expert central
review was performed using the five-point scale or
Deauville criteria (DC) with scores 1–3 regarded as CMR.
2y-event-free survival (EFS) according to interim PETat 2 cy-
cles was 75.9 % (63.7, 84.5) vs 41.4 % (28.7, 53.6) for pa-
tients with CMR and Deauville scores 4–5, respectively,
p<0.001. According to end-of-treatment PET, 2y-EFS was
71.5 % (61.2, 79.5) for CMR and 24.0 % (9.8, 41.7) for
Deauville scores 4–5. Of note is that all patients with CMR
on interim PET (60 %) remained in CMR at end of treatment
and the EFS for a negative PETwas very similar at interim and
end of treatment.
Similar findings were reported in an earlier study [41] and a
more recent study by Huntington et al. [39] where 79 % of
patients had CMR at interim, all of whom had CMR at end of
treatment. This confirms that interim PET shows CMR early
in a significant proportion of patients and supports the premise
that end-of-treatment scans are not necessary in patients who
have CMR at interim.
Another interesting study was reported by Carr et al. [29••]
combining interim (2–3 cycles) and end-of-treatment PET as-
sessment from an international cohort of patients with
DLBCL from disparate healthcare systems, sponsored by the
International Atomic Energy Agency. They set a priori criteria
which were similar, but not identical to DC. There was no
significant difference in outcomes by country according to
PET, suggesting that the technology is equally well applied
in low- and high-income countries. In 327 patients, interim
PETwas negative in 64 % and positive in 36 %. The authors
stratified 312 patients into four groups using the results of both
interim PETand end-of-treatment PET. The best outcome was
in the largest group (62 %) with interim and end-of-treatment
CMR; 2y-EFS was 97 % (92, 98). Over half the patients who
did not achieve CMR at interim had CMR at end of treatment
(19 %), and these ‘slow’ responders, in whom bulky disease
was more common, also had good outcomes, with 2y-EFS of
86 % (73, 93), although the hazard ratio (HR) for relapse
compared to the previous group was 2.56 (1.08–6.11). These
results imply that treatment escalation according to a positive
interim PET could significantly over-treat many patients.
Patients who had both positive interim PET and end-of-
treatment PET (16 %) had 2y-EFS of 35 % (22, 48). Finally,
13 (4 %) patients progressed on treatment, with negative
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interim but positive end-of-treatment scans, 11 with biopsy-
proven disease.
On the basis of these studies, it is clear that an early CMR
on interim PET identifies a group with excellent prognosis,
with the advantage of reassuring patients of the expected good
outcome early. On the other hand, approximately half of pa-
tients with a positive interim PET will enter remission and
change or escalation of treatment will over-treat an unaccept-
able proportion.
But more importantly is the fact that, to date, there has been
no alternative treatment that proved to be superior to R-CHOP.
In fact, studies which examined change or escalation on the
basis of interim PET have not shown any benefit. Five studies
have been reported either fully [42–44] or in abstract form [45,
46] using different PET criteria, timing and escalation strate-
gies, summarised in Table 1. These studies demonstrated two
findings: (1) the prognosis of interim PET positive is signifi-
cantly worse, and (2) there was no improvement in this prog-
nosis with changing therapy. The hope is that future research
may produce better regimens which improve the outcome of
patients not responding well to RCHOP. Until then, there is no
justification for an early change in therapy unless there is
definite evidence of progression.
So where does this leave the role of interim PET in
DLBCL? We assert that it is an excellent negative test, show-
ing remission early and enabling reassurance of patients whilst
still having treatment. In addition, it may show lack of any
response or early progression in a small proportion of patients.
Is it essential? The answer is no, but if interim imaging is
performed, we would recommend PET-CT in preference to
CT for the above reasons and recommend that if the result
shows CMR then an end-of-treatment-PET is not required,
which saves resources and inconvenience. On the other hand,
if the result is positive, there is no indication to change treat-
ment, but close monitoring of these patients during treatment
may be warranted, as a proportion of them may progress. In
our practice, if the initial disease was poor risk (e.g. high IPI)
and PET-2 is positive, we prefer to monitor the patient with
repeat PET after 4 cycles of treatment [9•].
PET for Pre-transplant Assessment
Various studies have reported that PET is predictive of out-
comes following high-dose chemotherapy before ASCT
[47–49], prior to DC, which are recommended by current
guidelines. Sauter et al. [50•] reported a retrospective analysis
of 129 patients with B-NHL, two thirds with DLBCL, who
underwent ASCT based on at least partial response using CT.
Scans were scored using DC. Patients with CMR and
Deauville scores 1–3 had 3y-PFS of 77 % and 3y-OS of
86 % compared to patients with Deauville scores ≥4 with
3y-PFS of 49 % and 3y-OS for 54 %, leading the authors to
conclude that patients with inadequate response on PET-CT
should be the focus of risk-adapted investigational therapies.
Follicular Lymphoma
FL is the second most common lymphoma type worldwide,
and although generally characterised by an indolent course, it
has a very varied natural history. With significant changes in
its management, particularly the introduction of monoclonal
antibodies and improvements in prognosis and overall surviv-
al, the paradigm of treatment is shifting from symptom palli-
ation to more active treatment with the aim of prolonging
remission and survival. Imaging modalities and accurate re-
mission assessment are therefore becoming more important.
In early stage disease, radiotherapy (RT) remains the stan-
dard treatment resulting in durable remissions and possibly
cure in almost half of patients staged without PET. Most re-
lapses occur outside the radiation field, indicating failure of
initial staging rather than RT. Therefore, more accurate staging
could help improve selection for RT and reduce the incidence
of relapse [51, 52•, 53, 54].
For advanced disease, watch and wait remains an option for
low-volume asymptomatic disease. Accurate assessment of
disease extent is important in this case, and criteria have been
developed to select patients suitable for this approach [55].
For patients with higher disease burden or symptoms, the
current standard approach is chemo-immunotherapy induc-
tion followed by 2 years of maintenance rituximab which
results in a long PFS for most patients. However, there are
probably a substantial number of patients who do not benefit
from prolonged maintenance and there is a small group of
patients (about 20 %) who relapse early within 2 years, even
after anthracycline-containing induction, and have a much
shorter OS [56]. Identifying those patients is important as they
need alternative treatment approaches. New therapeutic op-
tions have become available in the last decade including
new antibodies and agents targeting oncogenic pathways [57].
PET for Pre-treatment Staging
PET-CT detects more nodal and extranodal sites than CT in
patients with FL undergoing induction chemotherapy [52•].
The impact on staging is higher in patients with apparently
limited stage on CT in whom PET is performed (i) to deter-
mine if local RT treatment is appropriate (ii) to plan RT fields.
In a recent phase III prospective study which randomised pa-
tients to one of three R-chemotherapy treatments, PET-CT
altered the Follicular Lymphoma International Prognostic
Index (FLIPI) score in 35/142 patients, increasing the score
in 18% of patients overall and in 62% of patients (15/24) with
limited disease on CT [52•], confirming earlier reports [51, 53,
54]. Although outcomes from patients selected for RT using
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PET-CT have not been published, this would appear to be a
sensible indication for PET-CT in patients with FL. Bone mar-
row biopsy detected bone marrow involvement in 46/108
(43 %) of patients without marrow abnormalities on PET
[52•], indicating that BMB is required for diagnostic workup.
The ability of PET to select sites for biopsy in cases with
suspected transformation has also been previously described
[58, 59] and is recommended in current guidelines [2••].
Table 2 Role for PET-CT in
staging and restaging patients
with DLBCL and FL
DLBCL FL
Baseline PET used for:
Risk stratification Risk stratification
NCCN-IPI using PET discriminates patients with
very good prognosis from patients at high risk of
treatment failure, mostly elderly patients
unsuitable for salvage treatments for whom
testing with novel agents may be appropriate
PET-CT upstages patients compared
to CT; effect on outcomes not known
Parameters including number of extranodal sites
and metabolic tumour burden, also combined
with early response are promising predictors of
prognosis.
Staging including bone marrow assessment Staging
Can replace bone marrow biopsy in selected cases To assess suitability for local (RT) or systemic
treatment low sensitivity for bone marrow
assessment; bone marrow biopsy required
Mapping initial disease sites for accurate
response assessment
Mapping initial disease sites for accurate
response assessment
Differentiating lymphomatous involvement from
other causes for increased FDG uptake, e.g.
infection, inflammation, bone marrow
hyperplasia
Differentiating lymphomatous involvement from
other causes for increased FDG uptake,
e.g. infection, inflammation, bone marrow
hyperplasia
Interim PET used for:
Prognosis Prognostic but no current role
Early CMR has excellent prognosis and usually
predicts CMR at end of treatment; such patients
do not require end-of-treatment scans.
Patients with a positive interim PET and
other high risk features, e.g. poor-risk IPI, may
require close monitoring during treatment as they
have higher risk of refractory disease and relapse.
PET is a more appropriate test for interim imaging
assessment than CT.
Excluding disease progression on treatment
But should not be used to change standard
treatment unless clear evidence of progression. To
date, no evidence exists that response adaptation
at interim on the basis of positive PET improves
patient outcomes and risks over-treating many
patients.
End of treatment PET used for:
Remission assessment Remission assessment
Using Deauville criteria. Patients with end-of-
treatment Deauville scores 4 and 5 should be
considered for further treatment with biopsy
confirmation wherever feasible but particularly
if salvage treatment ± ASCT is being considered.
After induction treatment with R-CHOP(-like)
chemotherapy using Deauville criteria.
Patients with end-of-treatment Deauville
scores 4 and 5 have worse outcomes than
patients achieving CMR and may be suitable
for testing of response-adapted strategies.
Decision making as to suitability for ASCT
following high-dose chemotherapy
Early data suggest may be predictive of outcomes
after following high-dose chemotherapy prior
to ASCT.In preference to CT
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Response Assessment—PETat Interim, End of Treatment
and Prior to ASCT
PET-CTwas initially supported for response assessment in the
research setting [60] but has now become the standard imag-
ing modality [2••, 3••]. This was based on three multicentre
studies where PET-CTwas used to assess response in patients
with high tumour burden symptomatic FL or advanced dis-
ease, which included 122 [61], 112 [62] and 205 [63] patients,
respectively. All reported end-of-treatment PET-CT to be pre-
dictive of PFS, independent of the FLIPI and superior to CT-
based response. Interim PET (cycle 4) was predictive of PFS,
but not as strongly predictive as the end-of-treatment scan in
the prospective PET-Folliculaire study [62].
A pooled analysis of PET-CT response in the three studies,
using central scan review and DC, was published in 2014
[64••]. The analysis included 246 patients with PET-CT scans
available for review. Median FU was 54.8 m. Seventy-three
percent of patients were treated with R-CHOP, 15 % with R-
CVP and 12 % with R-FM. Eighty-three percent of patients
had a negative scan (Deauville scores 1–3). The study re-
vealed three important findings. Firstly, there was a significant
number of patients who had their response re-classified with
PET compared to CT-based International Working Group
(IWC) criteria. Of 128 patients with CR/CRu, 17 (13 %) had
Deauville scores 4–5, and of 72 with PR/SD/PD, 50 (69 %)
were re-classified as CMR (Deauville scores 1–3). Secondly,
the PET-based response was more predictive of PFS and OS
than IWC, in the whole group, in the RCHOP-treated patients
and in the responding patients according to IWC. In the whole
group, 4y-PFS was 63.4 % (55.9, 70.0) for patients with
CMR, compared with 23.2 % (11.1, 37.9) for patients without
CMR [HR 3.9 (2.5,5.9) p<0.0001]. The difference in median
PFS was very large: 74 and 16.9 months for patients with
scans showing CMR and no CMR, respectively. Finally,
PET-based response was an independent and stronger predic-
tor of PFS than FLIPI and IWC response.
These data establish PET-CT as the imaging modality of
choice for remission assessment in FL, but more importantly,
it shows that PET response using DC can identify the small
group of patients who are likely to have an early progression
(median PFS 16.9 m). As discussed in the BIntroduction^
section, it has been shown that patients who progress within
2 years have worse OS (5y-OS 50 % compared to 90 % for
longer remission) [56] who may be candidates for close mon-
itoring and testing different treatment approaches if they re-
lapse early. Patients with CMR can be confidently reassured
about the prospect of long PFS. The discriminatory ability of
PET response to first-line therapy in FL lends itself to being
used in studies testing response-adapted therapy, further refin-
ing the management of this disease with varied natural history.
Lastly, salvage treatment and ASCT is an option for pa-
tients with refractory or relapsed disease who are sufficiently
fit. An initial report from the Lymphoma Studies Association
in 59 patients with relapsed/refractory disease after first-line
R-CHOP suggested that PET may be able to predict response
following high-dose chemotherapy prior to ASCT [65], as
previously reported in HL and DLBCL.
Conclusions (Table 2)
In DLBCL:
1. PET-CT can be used with prognostic indices to risk-
stratify patients [5]. Poor risk is best predicted using the
NCCN-IPI [5, 6], but this group consists of elderly pa-
tients unfit for salvage treatments in whom novel agents
may be explored [6].
2. The number of extranodal sites, including bone marrow
involvement [5] and disease burden using MTV [9•, 17,
18], are promising baseline predictor of prognosis using
PET, which can be combined with early response assess-
ment [9•].
3. CMR on interim PET is predictive of excellent prognosis
and allows patients on treatment to be reassured. Such
patients do not require end-of-treatment PET [28••, 29••,
38, 39]. Treatment escalation, however, when patients do
not have early CMR, is unjustified [29••, 42–46], but
closer monitoring, especially for patients with other high
risk features, may be appropriate.
4. End-of-treatment PET is better for remission assessment
than CT. Patients who do not achieve end-of-treatment
CMR should be considered for further treatment after bi-
opsy confirmation, where feasible [28••].
In FL:
5. PET-CT is more sensitive for staging than CT [52•] and
can be used to select biopsy sites in clinically suspected
transformation [58, 59].
6. PET-CT identifies patients at increased risk of early
progression following induction chemotherapy with
R-CHOP(like) therapy [64••] and would be suitable
to select patients for response-adapted trials testing
new agents.
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